Quark Pharmaceuticals Inc., of Fremont, Calif., said a phase II trial of QPI-1002, a synthetic chemically modified siRNA acting to temporarily reduce p53 expression for the prophylaxis of acute kidney injury (AKI) following cardiac surgery, met its primary endpoint of reducing the incidence of AKI through day five.